


CTC Director to Lead COVID19 Study
CLARITY 2.0 study looks at the Dimerix lead candidate DMX-200 combined with Angiotensin Receptor Blockers to treat respiratory issues associated with COVID19.
Read More

To recover your password please fill in your email address
Please fill in below form to create an account with us
CLARITY 2.0 study looks at the Dimerix lead candidate DMX-200 combined with Angiotensin Receptor Blockers to treat respiratory issues associated with COVID19.
Read More12/11/20
22/10/20
13/08/20